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Sodium alendronate is an antiresorptive drug used for the treatment of postmenopausal osteoporosis. 
However, its oral administration is associated with low bioavailability and gastroesophageal irritation. 
This work aimed at developing tablets containing sodium alendronate-loaded microparticles by direct 
compression to achieve a safe and effective form. The parameters evaluated were average weight, 
hardness, thickness and drug content. In vitro release tests were carried out using simulated gastric and 
intestinal fluids, and the profiles were analyzed through the Korsmeyer-Peppas mono- or biexponential 
dependent approaches. Tablets presented adequate average weight, thickness, good mechanical properties 
and drug content close to 100%. Moreover, the formulation released less than 11% of sodium alendronate 
in gastric fluid, exhibiting a good gastroresistance. At pH 6.8, almost 100% of the drug was released in 
12h, showing a prolonged profile. The mathematical modeling indicated that the experimental data was 
better fitted to the biexponential equation. Furthermore, a good correlation coefficient was obtained for 
the Korsmeyer-Peppas model and the release exponent suggested that the drug dissolution was driven 
by anomalous transport. In conclusion, the microparticulated tablets can be considered a promising 
alternative for oral delivery of sodium alendronate.
Uniterms: Microparticulated tablets/release profile. Sodium alendronate/oral administration. Sodium 
alendronate/controlled release/in vitro study.
O alendronato de sódio é um fármaco da classe dos bisfosfonatos, comumente utilizado no tratamento da 
osteoporose pós-menopausa. Entretanto, sua administração oral está associada à baixa biodisponibilidade 
e irritação gastroesofágica. Este trabalho objetivou o desenvolvimento de comprimidos contendo 
micropartículas de alendronato de sódio por compressão direta, a fim de obter uma forma segura e eficaz. 
Os parâmetros avaliados foram peso médio, dureza, espessura e teor de fármaco. Estudos de liberação in 
vitro foram realizados utilizando fluído gástrico e intestinal simulado e o perfil de liberação foi analisado 
pelos modelos matemáticos de Korsmeyer-Peppas, mono- e biexponencial. Os comprimidos apresentaram 
peso médio adequado, espessura, dureza e teor próximo a 100%. Além disso, a formulação liberou menos 
de 11% do fármaco em fluído gástrico, mostrando uma boa gastrorresistência. Em pH 6,8, em torno de 
100% do fármaco foram liberados em 12 h, apresentando liberação prolongada. A modelagem matemática 
indica que os resultados seguem a equação biexponencial. Pela análise do expoente de liberação obtido 
no modelo de Korsmeyer-Peppas sugere-se que a dissolução do fármaco ocorre por transporte anômalo. 
Concluindo, a preparação dos comprimidos microparticulados pode ser considerada uma alternativa 
promissora para a liberação oral do alendronato de sódio.
Unitermos: Comprimidos microparticulados/perfil de liberação. Alendronato de sódio/administração 
oral. Alendronato de sódio/liberação controlada/estudos in vitro.
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INTRODUCTION
Sodium alendronate is an antiresorptive drug 
belonging to the class of bisphosphonates used to prevent 
and treat postmenopausal osteoporosis (Perez-Lopez, 
2004). Sodium alendronate is marketed as tablet. However, 
it presents poor oral absorption and upper gastrointestinal 
adverse events, such as esophageal and gastric irritation, 
the major reasons for the discontinuation of the therapy 
(Li, Kendler, 2004).
To prevent the side effects and to maximize its 
absorption, sodium alendronate tablets should be taken 
with a full glass of water, and patients should not lie 
down for at least 30 min after ingestion. Moreover, no 
food should be eaten immediately after the ingestion 
of this medicine (Li, Kendler, 2004). These dosing 
recommendations are associated with poor therapeutic 
adherence (Reginster, Rabenda, Neuprez, 2006). In 
this context, the design of a drug carrier with suitable 
properties could be a promising alternative for the oral 
delivery of bisphosphonates.
In a previous work (Cruz et al., 2010), we reported the 
preparation of sodium alendronate-loaded microparticles 
by spray-drying. The formulation was composed of a 
blend of Eudragit S100®, an enterosoluble polymer, and 
Methocel K15M®, a controlled release cellulose derivative. 
In vitro release experiments showed that the microparticles 
presented an adequate gastroresistance combined with a 
prolonged drug release for 12h. After oral administration 
to rats, drug-loaded microparticles were able to prevent 
the bone loss in ovariectomized animals. Moreover, rats 
that received sodium alendronate-loaded microparticles 
exhibited an ulcerative lesion index significantly lower 
compared to the group treated with the drug solution. 
Therefore, these microparticles were considered promising 
carriers for the oral delivery of sodium alendronate.
Despite the great potential presented by the 
microparticles, this type of drug delivery system is rarely 
used directly in its powdered form. For this reason, 
the goal of the present study was the preparation and 
characterization of tablets containing sodium alendronate-
loaded blend microparticles. The development of this type 
of formulation is considered a difficult task, due to the fact 
that the particle must withstand the compression force in 
order to avoid its rupture or deformation with consequent 
loss of gastroresistance and increased dissolution rates. 
The deformation or rupturing of microparticles after 
compression is the reason why only a few microparticulate 
formulations are commercially available. In addition, 
tablets were chosen as the final dosage form due to their 
popularity, convenience of dosing, ease of manufacture, 
stability and release mechanism (Jivraj, Martini, Thomson, 
2000).
MATERIAL AND METHODS
Material
Monosodium alendronate trihydrate was purchased 
from Pharma Nostra (São Paulo, Brazil). Methocel® 
K15M (hydroxypropyl methylcellulose) was kindly 
donated by Colorcon (Cotia, Brazil), and Eudragit® 
S100 (Poly(methacylic acid-co-methyl methacrylate) 
1:2 ) was obtained from Degussa (São Paulo, Brazil). 
o-Phtalaldehyde (OPA) was purchased from Sigma-
Aldrich (São Paulo, Brazil), and 2-mercaptoethanol 
was acquired from Acros Organics (Geel, Belgium). 
Microcrystalline cellulose (Avicel® PH101) was 
purchased from FMC corporation (Philadelphia - 
USA), poly(vinyl pyrrolidone) (PVP - Kollidon® 30) 
from Delaware (Porto Alegre - Brazil), and stearate 
magnesium was obtained from Henrifarma (São Paulo - 
Brazil). All other solvents and reagents were of analytical 
grade and used as received.
Preparation and characterization of 
microparticles
Sodium alendronate-loaded microparticles (n=3) 
were prepared by spray-drying, as previously described 
(Cruz et al., 2010). Briefly, Eudragit® S100 (5.0 g) was 
dissolved in 0.05 mol/L NaOH (500 mL) under magnetic 
stirring at 50°C. Then, Methocel® K15M (2.5 g) was added, 
and the mixture remained under mechanical stirring for 
15 min. The formed gel was kept at 4 °C for 24 h. Sodium 
alendronate (2.0 g) was added in the gel before spray-
drying. Operational conditions were the following: feed 
rate of 0.33 L/h, air flow rate of 70 nL/h, atomizing air 
pressure of 3.0 kgf/cm, inlet temperature of 150 °C and 
nozzle diameter of 1.2 mm. The resultant powders were 
stored in a desiccator. The yield was calculated by the ratio 
of the experimental weight and the sum of the weights of all 
components, disregarding the water content. Encapsulation 
efficiency was determined spectrophotometrically at 
333 nm using OPA as derivatizing agent (Cruz et al., 2009). 
Size and size distributions of microparticles were analyzed 
by laser diffractometry (Malvern Mastersizer, 2000 Inserir 
referência na parte reference, Malvern Instruments, UK). 
Moisture content was assayed using an infrared drying 
equipment (Gehaka IV 2500) kept at 115 °C until constant 
weight. Bulk density (ρb) was determined by transferring 
2.0 g of microparticles to 25 mL graduated cylinder. The 
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powder volume was determined and then the bulk density 
was calculated. The sample contained in the measuring 
cylinder was tapped 1250 times using a Pharmatest PT-TD 
to obtain the tapped density (ρt). Carr index and Hausner 
ratio were determined from the values of the bulk and tapped 
densities results.
Preparation and characterization of tablets 
containing microparticles
Tablets with theoretical weight of 750 mg were 
prepared by the direct compression of powders. Previously, 
an amount of microparticle corresponding to 70 mg of 
sodium alendronate was mixed with microcrystalline 
cellulose (12%) as diluent, PVP (15%) as dry binder, and 
magnesium stearate (0.75%) as lubricant in a glass mortar. 
A single punch machine (Neuberger) was used for powder 
compression. An exact amount of the powder mixture was 
filled in a die using a little pressure and then, hydraulic 
pressure (400 kgf/cm2) was employed to form the tablets. 
After the preparation, tablets were characterized according 
to average weight (analytical balance - Shimadzu AY220), 
thickness (manual caliper), hardness (portable hardness 
tester Off Tec Galileo) and drug content using the same 
method mentioned for the microparticles. In vitro release 
tests were carried out using USP Apparatus 1: basket, 
100 rpm at 37 °C (USP, 2008). The gastroresistance of 
the tablets was evaluated in 900 mL of simulated gastric 
fluid, compound 0.1 mol/L HCl (pH 1.2), until 2 h of 
experiment, while dissolution profile was studied in 
900 mL of simulated intestinal fluid, containing phosphate 
buffer pH 6.8, during 12 h. The drug dissolved at specified 
periods was plotted as percent release versus time curve. 
Sodium alendronate release was analyzed by model-
dependent approaches: monoexponential (Equation 1) and 
biexponential (Equation 2).
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where Mt is the amount of the drug released at time t, M∞ 
is the initial concentration of the drug, k, α and β are the 
apparent release kinetic rate constants, A and B are the 
fractions of the drug that contributed to the burst and 
sustained phases, respectively.
The release mechanism of sodium alendronate 
from tablets was analyzed by fitting experimental data to 
Korsmeyer-Peppas model (Equation 3).
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where ft is the ratio of the absolute cumulative amount of 
drug released at time t and at infinite time, k is a constant 
incorporating structural and geometric characteristic of 
the carrier, and n is the release exponent, indicative of the 
drug release mechanism.
In all cases, the fit was performed using the Scientist 
2.0 software (Micromath, USA). The selection of the 
model was based on the best correlation coefficient and 
the best model selection criteria (MSC), both provided by 
the software, and the best graphic adjustment.
Statistical analysis
The data were analyzed by Student’s t-test, one-
way and two-way ANOVA. Significance level was set at 
p < 0.05.
RESULTS AND DISCUSSION
Following preparation, microparticles were 
presented as finely divided white powder. Regardless of 
the presence of the drug, the formulations were obtained 
with a yield of about 40%. Powder loss may be due to the 
adhesion of sprayed droplets to the internal walls of the 
equipment and the poor efficiency of cyclone in collecting 
fine particles. Sodium alendronate-loaded microparticles 
had encapsulation efficiency of 85.7 ± 0.9%, which 
corresponds to a drug loading of 155.7 ± 1.7 mg/g. In 
our previous work (Cruz et al., 2010), we reported a 
lower encapsulation efficiency of 79.7 ± 0.9%, despite 
the same operational conditions. Regarding particle 
size, the mean diameter (d4,3 = 5.8 µm) and span (1.5) 
found in this work were lower than the values previously 
reported (Cruz et al., 2010). These differences found 
for encapsulation efficiency and particle diameters are 
associated with the fact that the spray-dryer used here is 
not the same equipment employed for the preparation of 
microparticles in our previous work. Concerning moisture 
content, this parameter was evaluated for the first time 
for sodium alendronate-loaded blended microparticles 
and showed water content of 6.35 ± 0.1%. As for powder 
densities, the microparticles showed 0.12 ± 0.01 g/cm3 
and 0.19 ± 0.03 g/cm3 for bulk and tapped density, 
respectively. The flow properties are expressed in terms of 
Carr index and Hausner ratio. Sodium alendronate-loaded 
microparticles presented Carr index of 36.8 ± 0.04% and 
Hausner ratio of 1.57 ± 0.10. Both values indicate poor 
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flow properties. However, the addition of excipients can 
improve powder flowability.
In order to prepare tablets containing sodium 
alendronate-loaded microparticles, previous trials were 
performed to select the best diluent (starch, lactose 
and microcrystalline cellulose) and the optimal PVP 
concentration (2.5, 5.0, 10.0 and 15.0%). Results showed 
a great variation in tablet weight using lactose or starch 
(data not shown). Moreover, PVP concentrations below 
15.0% resulted in tablets with low hardness (less than 
3.0 kgf). On the other hand, tablets presenting good 
mechanical properties and low weight variation were 
obtained using microcrystalline cellulose as diluent and 
15.0% of PVP as dry binder. After preparation, the tablets 
containing microparticles presented an average weight 
of 748 ± 19 mg, thickness of 0.4 ± 0.0 cm, adequate 
hardness of 9.2 ± 0.3 kgf, and sodium alendronate content 
of 99 ± 10%. As previously reported, the increase in the 
PVP concentration resulted in improved tablet hardness 
(Patel, Amin, 2011). In addition, cellulose can significantly 
improve tablet hardness, due to its plastic properties 
(Zhang, Law, Chakrabarti, 2003).
For gastroresistance check, tablets containing 
microparticles were evaluated in simulated gastric fluid. 
Within 120 min, 10.9% of sodium alendronate was 
released from tablets (Figure 1). Although a little portion 
of drug was released, this result is in accordance with 
the United States Pharmacopoeia specifications. On the 
other hand, dissolution profiles at pH 6.8 showed that the 
totality of the drug was released in 720 min (Figure 1). The 
in vitro releases of sodium alendronate showed here are 
very similar to those reported for untableted microparticles 
(Cruz et al., 2010). The similarity of results obtained for 
microparticles before and after compression suggests 
that when microparticles were tableted, the particles 
remained intact within the tablet without undergoing major 
deformation and hence, drug release took place from the 
individual microparticles.
In order to understand the dissolution profile, data 
were fitted to mono- and biexponential equations. By 
comparing the values of correlation coefficient and MSC 
(Table I), the release of sodium alendronate was better 
described by the biexponential equation. In this case, the 
release profile presents two phases, the first step, related 
to the burst effect (apparent rate constant α), and the 
other one corresponding to the slow phase (apparent rate 
constant β). Results showed that about 10% of the drug is 
responsible for the burst effect with a kinetic constant α 
of 0.4122 ± 0.0009 min-1, while the major part of sodium 
alendronate (90%) was released in the slow phase with a 
kinetic constant β of 0.0028 ± 0.0011 min-1. It is important 
to mention that untableted microparticles also followed 
biexponential behavior. However, 15% of the drug was 
associated with the burst effect, while approximately 85% 
of sodium alendronate was released in the slow phase.
To understand the drug release mechanism, 
data were also fitted to the Korsmeyer-Peppas model. 
Regarding the literature (Peppas, 1985), values of release 
exponent n ranging from 0.43 to 0.85 indicate anomalous 
transport. Thus, sodium alendronate release from tablets 
containing microparticles is driven by polymer relaxation 
TABLE I - Parameters of mathematical modeling
Models/Parameters
Monoexponential
k (min-1) 0.0033 ± 0.0004
r 0.9805
MSC 2.7401
Biexponential
α (min-1) 0.4122 ± 0.0009
β (min-1) 0.0028 ± 0.0011
A 0.0998 ± 0.0015
B 0.9004 ± 0.0010
r 0.9901
MSC 3.5219
Korsmeyer-Peppas
k 0.047 ± 0.011
n 0.523 ± 0.017
r 0.9937
FIGURE 1 - Dissolution profiles of sodium alendronate from 
tablets containing microparticles at pH 1.2 and pH 6.8.
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and drug diffusion (anomalous behavior), as observed for 
untableted formulation.
CONCLUSION
Sodium alendronate-loaded blend microparticles 
were successfully tableted showing adequate technological 
properties. Therefore, the gastroresistant tablets can be 
considered a promising formulation to be used in the oral 
treatment of osteoporosis. Further preclinical and clinical 
studies are needed to confirm its therapeutic potential.
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